---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-132925"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T21:28:16.189919+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma raises up to $72.6M; initial $20M tranche to fund Bird Flu drug

## Summary
- Initial $20M gross proceeds from common stock and pre-funded warrants; net proceeds ~$17.9M.
- Up to $52.6M additional from Series A Warrants exercisable after key Bird Flu data readouts (Ferret, NHP, Phase 2a).
- Institutional investors: Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines, Ikarian Capital.
- Proceeds to accelerate Tivoxavir Marboxil development; cash runway extended into 1H26 (initial) and 3+ years if warrants exercised.
- Closing on Dec 31, 2024; Series A Warrants subject to stockholder approval and 9.99% ownership limitation.

## SEC filing metadata
- accession: 0001104659-24-132925
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465924132925/0001104659-24-132925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465924132925/tm2432248d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-132925
- JSON: https://secwatch.observer/filing/0001104659-24-132925.json
- Plain text: https://secwatch.observer/filing/0001104659-24-132925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.